Cargando…

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses

More than two years after the emergence of SARS-CoV-2, 33 COVID-19 vaccines, based on different platforms, have been approved in 197 countries. Novel variants that are less efficiently neutralised by antibodies raised against ancestral SARS-CoV-2 are circulating, highlighting the need to adapt vacci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roth, Nicole, Schön, Jacob, Hoffmann, Donata, Thran, Moritz, Thess, Andreas, Mueller, Stefan O., Petsch, Benjamin, Rauch, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414064/ https://www.ncbi.nlm.nih.gov/pubmed/36016139 http://dx.doi.org/10.3390/vaccines10081251

Ejemplares similares

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
por: Hoffmann, Donata, et al.
Publicado: (2021)

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Rauch, Susanne, et al.
Publicado: (2021)

Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma
por: Davis, Samantha K, et al.
Publicado: (2022)

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccination
por: Hollstein, Moritz M., et al.
Publicado: (2022)

Neutralisation of SARS‐CoV‐2 by anatomical embalming solutions
por: Quondamatteo, Fabio, et al.
Publicado: (2021)

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
por: Kemp, SA, et al.
Publicado: (2020)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Long‐term effects of homologous and heterologous SARS‐CoV‐2 vaccination on humoral and cellular immune responses
por: Hollstein, Moritz M., et al.
Publicado: (2022)

Neutralisation de Sars-CoV-2 Delta après vaccination hétérologue
por: Manus, Jean-Marie
Publicado: (2021)

SARS-CoV-2 neutralising antibodies in dogs and cats in the United Kingdom
por: Smith, Shirley L., et al.
Publicado: (2021)

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021)

SARS-CoV-2 neutralising antibodies in Dogs and Cats in the United Kingdom
por: Smith, Shirley L., et al.
Publicado: (2021)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients
por: Honfi, Dániel, et al.
Publicado: (2022)

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
por: Tonn, Torsten, et al.
Publicado: (2020)

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
por: Pang, Natalie Yan-Lin, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
por: Souza, William M, et al.
Publicado: (2021)

Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel
por: Park, Sungsoo, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations
por: Trombetta, Claudia Maria, et al.
Publicado: (2022)

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
por: Corleis, Björn, et al.
Publicado: (2023)

An optimised protocol for detection of SARS-CoV-2 in stool
por: Li, Tianqi, et al.
Publicado: (2021)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies
por: Müller, Katharina, et al.
Publicado: (2021)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities
por: Moyet, J., et al.
Publicado: (2021)

Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera
por: Brandolini, Martina, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation
por: Seow, Han Cong, et al.
Publicado: (2023)

Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
por: Barnes, Thomas W., et al.
Publicado: (2021)

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
por: Carnell, George W., et al.
Publicado: (2023)

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2
por: Müller, Katharina, et al.
Publicado: (2021)

Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
por: Atmar, Robert L., et al.
Publicado: (2021)

Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria
por: Eggenhuizen, Peter J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_au829at45pf1jbu688bbb51o83